Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy.
Matthew F WippermanKaitlyn M GayvertAmanda AtanasioClaire Q WangJonathan CorrenAngelica CovarrubiasIan SetliffErica ChioElizabeth LawsKelley WolfeSivan HarelJennifer MaloneyGary HermanJamie M OrengoWei Keat LimSara C HamonJennifer D HamiltonMeagan P O'BrienPublished in: Allergy (2024)
These results demonstrate type 2 inflammation is an important contributor to the pathophysiology of AR disease and that inhibition of the type 2 pathway with dupilumab may normalize nasal tissue gene expression.